Pharmacyte Biotech Inc (OTCMKTS:PMCB) witnessed another lift during the last session following a research report that highlighted the company’s prospects. It was not Goldman Small Cap Research this time, but Stock Market Media Group that has come up with a latest research report on the company. However, instead of focussing on the company’s diabetes treatment, the report centers around another ongoing clinical trial that will pave the way for it to enter into human clinical trials.

Pre-clinical trials are on

The research note throws light on the fact that the Silver Spring, Maryland biotech’s successful completion of follow-up preclinical study might put the company at the forefront of entering into Phase 1 human clinical trials. The research noted that the said trial is aimed to treat “quality of life” symptom, which exists in patients of abdominal cancer. The research firm detailed that the pre-clinical study is currently carried out at the Translational Drug Development (TD2) in Arizona, under the guidance of oncologist Dr. Daniel Von Hoff.

The trial is observing four groups of mice, which are implanted with human cancer cells. The agenda of the pre-clinical study is to arrive at a conclusion on whether Pharmacyte Biotech Inc (OTCMKTS:PMCB)’s pancreatic cancer treatment is effective in containing the accumulation of dangerous fluid. The treatment involves a combination of Pharmacyte Biotech Inc (OTCMKTS:PMCB)’s Cell-In-A-Box therapy and ifosfamide.

Better results

The report cited that as per preliminary data, the company has confirmed that its treatment has returned results of significant survival advantage in the group of mice. At the same time, the company’s treatment came in line with cisplatin, which is the existing standard of care in cancer patients. The report indicated that the company’s therapy may become the standard of care for malignant ascites if the follow-up pre-clinical trial adds up to the prior pre-clinical trial.

The stock of Pharmacyte Biotech Inc (OTCMKTS:PMCB) ended 1.85% higher at $0.165 during the last trading session, while an average volume of shares remained 5 million.